Fig. 1From: Agnostic evaluation of ipilimumab and nivolumab association: a metanalysisGlobal ORR Analysis. Figure shows ORR analysis in selected trials. ORR was highly favoring the combination of nivolumab plus ipilimumab with respect to nivolumab alone (OR = 1.683; 95% CI: 1.407–2.012; P < 0.0001). Fixed effect model—Heterogeneity not significant (P = 0.62). *Nivo 3 mg + IPI 1 mg. **Nivo 1 mg + IPI 3 mgBack to article page